CLL-Current and Emerging Therapies

Article

Please join us for our upcoming telephone/web education program, CLL- Current and Emerging Therapies on, Wednesday, June 18, 2014 1:00-2:30 pm EST featuring Thomas Kipps, MD, Deputy Director for Research at the University of California Moores Cancer Center.

Thomas Kipps, MD

Please join us for our upcoming telephone/web education program,

CLL- Current and Emerging Therapies

on, Wednesday, June 18, 2014 1:00-2:30 pm EST featuring Thomas Kipps, MD, Deputy Director for Research at the University of California Moores Cancer Center.

Topics will include:

  • The goal of CLL treatment
  • How staging influences personalized treatment planning
  • Current treatment options for CLL
  • Emerging therapies and clinical trials for CLL
  • Side effects management
  • The importance of open communication with your treatment team

For more information, please contact the Leukemia & Lymphoma’s Information Resource Center at 800-955-4572 or

www.LLS.org/programs

.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
Elizabeth Aronson
Shivani Gopalsami
Donna Catamero
Related Content
Graphic of a leukemia cell

FDA Relaxes REMS, Monitoring Rules for Liso-Cel and Ide-Cel

Chris Ryan
June 28th 2025
Article

The FDA removed REMS and reduced certain monitoring needs for liso-cel and ide-cel in B-cell malignancies.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Illustration of two medical workers holding up a magnifying glass to a cross-section of a bone

Subcutaneous Daratumumab Could Mark First Smoldering Myeloma Treatment

Bridget Hoyt
June 21st 2025
Article

Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma. Here’s what nurses should know.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Lindsay Fischer
December 1st 2023
Podcast

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

Image of blood cells

Fast Track Status Given to Givinostat for Polycythemia Vera

Tim Cortese
May 11th 2025
Article

The safety and efficacy of givinostat is being assessed vs hydroxyurea in the phase 3 GIV-IN PV trial.

Line illustration of a clipboard that says "FDA" with an approval mark in front on a cornflower blue background

A Snapshot of April FDA Approvals in Oncology for Nurses and APPs

Bridget Hoyt
May 1st 2025
Article

Approvals in oncology during April included treatments for breast cancer, colorectal cancer, and more.